A Phase 2 interventional study of Brensocatib 10 mg and Brensocatib 25 mg in Non-Cystic Fibrosis Bronchiectasis, sponsored by Insmed Incorporated. Completed at 108 sites in 14 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-03-27.
Sponsored by Insmed Incorporated · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in Bronchiectasis with a site in United States — 21 open to participants now, 23 under way, 2 of them phase 3. Bronchiectasis · United States.
Among the 65 studies in Bronchiectasis with a site in United States, this one is the 19th largest by enrollment of the 52 interventional ones that give a count, is one of 2 that started in 2017, is one of 15 in phase 2, and was the 27th registered.
404 studies on the registry are indexed under Bronchiectasis; 125 are open to participants now.
Browse Bronchiectasis studies →21 of the 65 studies in Bronchiectasis with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
UCB Biopharma SRL · Sites in United States
Ages 18–80
Indiana University · Sites in United States
Ages 18+
AstraZeneca · Sites in United States, Argentina, Australia and 22 more countries
Ages 12+
GlaxoSmithKline · Sites in United States, Argentina, China and 9 more countries
Ages 18–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 93 Bronchiectasis studies recruiting now, 50 (54%) set no upper age limit and 13 (14%) stop at 75 or younger; 12 take children under 18; 26 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
First in 1988; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 256 is above the median of 60 across 263 interventional studies indexed under Bronchiectasis.
Median enrollment 78 across the 52 interventional studies, 100 across the 13 observational. Of the 39 that completed or were terminated, 20 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 65 have an industry lead sponsor. The 10 most frequent:
Insmed Incorporated is the lead sponsor of 50 studies on the registry; 8 are open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 8 (29%) have results posted.
Insmed Incorporated has 4 studies filed under Bronchiectasis — fewer than ten, so there is no comparison to draw.
8 of the studies in Bronchiectasis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06872892Phase 3Boehringer IngelheimThe AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis | 2027-06-15 |
| NCT05860803Mayo ClinicBreathing Training and Exercise Capacity in Non-CFB | 2026-12-01 |
| NCT07135284Synchrony-Medical, LtdReal Life Evaluation of the LibAirty Airway Clearance System in Adults With Bronchiectasis (RELACS) | 2027-02 |
| NCT05846230Boehringer IngelheimClairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine | 2027-03-31 |
| NCT03839992Gelb, Arthur F., M.D.Detection of Unsuspected Small Airways Obstruction in Cystic Fibrosis | 2027-04-25 |
Add all 8 to your calendar (.ics) → With an account.
Among the 65 studies in Bronchiectasis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate if INS1007 can reduce pulmonary exacerbations over a 24-week treatment period in participants with non-cystic fibrosis bronchiectasis.
Phase 2 randomized, double-blind, placebo-controlled, parallel-group, multicenter, multi-national study to assess the efficacy, safety and tolerability, and pharmacokinetics (PK) of INS1007 administered once daily for 24 weeks in participants with non-cystic fibrosis bronchiectasis (NCFBE).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received brensocatib 10 mg once daily (QD) before breakfast, for 24 weeks.
Drug: Brensocatib 10 mg
Participants received brensocatib 25 mg QD before breakfast, for 24 weeks.
Drug: Brensocatib 25 mg
Participants received the matching placebo QD before breakfast, for 24 weeks.
Drug: Placebo
Administered once per day for 24 weeks
Administered once per day for 24 weeks
Administered once per day for 24 weeks
Time to the First Pulmonary Exacerbation Over 24-Week Treatment Period
Time to first pulmonary exacerbation was calculated as the number of days from the date of randomization to the date of first documentation of an exacerbation. Pulmonary exacerbation was defined as having 3 or more of the following symptoms for at least 48 hours resulting in a physician's decision to prescribe antibiotics: 1. Increased cough 2. Increased sputum volume or change in sputum consistency 3. Increased sputum purulence 4. Increased breathlessness and/or decreased exercise tolerance 5. Fatigue and/or malaise 6. Hemoptysis A minimum of 4 weeks must have occurred between one exacerbation onset and the next. Any exacerbation that occurred less than 4 weeks from the prior exacerbation was not considered a new exacerbation. The analysis was performed using the stratified log rank test and using Kaplan Meier (KM) curves.
Time frame: Baseline (Day 1) to Week 24
Change From Baseline in Quality of Life Questionnaire - Bronchiectasis (QOL-B) Respiratory Symptoms Domain Score Over 24 Week Treatment Period
The QOL-B is a validated, self-administered patient reported outcome (PRO) that assesses symptoms, functioning, and health-related (HR) QOL for participants with non-cystic fibrosis bronchiectasis (NCFBE). The QOL-B contains 37 items in 8 domains (Respiratory Symptoms, Physical Functioning, Role Functioning, Emotional Functioning, Social Functioning, Vitality, Health Perceptions and Treatment Burden). Each of the 37 items is scored from 1 to 4, and each of the 8 domains scale scores is standardized on a 0-100 point scale, with higher scores representing fewer symptoms or better functioning and HR QoL. A positive change from Baseline indicates improvement in symptoms. For this outcome measure, change in the respiratory symptoms domain score from Baseline was reported. The analysis was based on mixed model for repeated measures (MMRM) approach.
Time frame: Baseline (Day 1) to Week 24
Change From Screening in Post-Bronchodilator Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) Over 24-Week Treatment Period
FEV1 was used to assess lung function and is the maximum amount of air that can be forced out in one second after taking a deep breath. The percent predicted FEV1 was calculated by converting the spirometer reading to a percentage of what would be predicted as normal FEV1 based on a several personal factors (e.g. sex, age, etc.). Change from screening in percent predicted FEV1 to Week 24 was calculated as: percent predicted FEV1 value at Week 24 and percent predicted FEV1 value at screening. A positive percent change from screening indicates an improvement in lung function. The analysis was done using analysis of covariance (ANCOVA) with Pa colonization status and maintenance macrolide antibiotic use at Baseline as covariates.
Time frame: Screening (Days -42 to -1) to Week 24
Change From Baseline in Concentration of Active Neutrophil Elastase (NE) in Sputum
The concentration of active NE in sputum, was measured by the difference between the pre-treatment concentration and on-treatment concentration. In bronchiectasis, activation of neutrophils in the airway leads to release of NE which leads to damaged airway walls, mucus hypersecretion, exacerbated inflammation, which in turn affects neutrophil and macrophage functions, increasing the risk of infection. Negative change from Baseline indicates improvement.
Time frame: Baseline (Day 1) to Week 24
Number of Participants Who Experienced a Pulmonary Exacerbation
Pulmonary exacerbation was defined as having 3 or more of the following symptoms for at least 48 hours resulting in a physician's decision to prescribe antibiotics. 1. Increased cough 2. Increased sputum volume or change in sputum consistency 3. Increased sputum purulence 4. Increased breathlessness and/or decreased exercise tolerance 5. Fatigue and/or malaise 6. Hemoptysis A minimum of 4 weeks must have occurred between one exacerbation onset and the next. Any exacerbation that occurred less than 4 weeks from the prior exacerbation was not considered a new exacerbation.
Time frame: Baseline (Day 1) to Week 24
Participants took part in the trial at 116 sites in 14 countries from 31 October 2017 to 12 December 2019.
| Milestone | Brensocatib 10 mg | Brensocatib 25 mg | Placebo |
|---|---|---|---|
| Started | 82 | 87 | 87 |
| Received study treatment (safety population) | 81 | 89 | 85 |
| Participants did not receive drug | 0 | 0 | 1 |
| Pharmacodynamic (pd) population | 80 | 89 | 84 |
| Completed | 76 | 75 | 74 |
| Not completed | 6 | 12 | 13 |
| Withdrew: Adverse event | 3 | 3 | 2 |
| Withdrew: Subject withdrew consent | 2 | 4 | 10 |
| Withdrew: Physician decision | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Withdrew: Reason missing | 0 | 2 | 0 |
| Withdrew: Death | 0 | 1 | 0 |
| Withdrew: Non-compliance with study drug | 0 | 1 | 0 |
Time to first pulmonary exacerbation was calculated as the number of days from the date of randomization to the date of first documentation of an exacerbation. Pulmonary exacerbation was defined as having 3 or more of the following symptoms for at least 48 hours resulting in a physician's decision to prescribe antibiotics: 1. Increased cough 2. Increased sputum volume or change in sputum consistency 3. Increased sputum purulence 4. Increased breathlessness and/or decreased exercise tolerance 5. Fatigue and/or malaise 6. Hemoptysis A minimum of 4 weeks must have occurred between one exacerbation onset and the next. Any exacerbation that occurred less than 4 weeks from the prior exacerbation was not considered a new exacerbation. The analysis was performed using the stratified log rank test and using Kaplan Meier (KM) curves.
| days | Brensocatib 10 mg | Brensocatib 25 mg | Placebo |
|---|---|---|---|
| Time to the First Pulmonary Exacerbation Over 24-Week Treatment Period | NA (NA to NA) | NA (NA to NA) | 189.0 (141.0 to NA) |
The QOL-B is a validated, self-administered patient reported outcome (PRO) that assesses symptoms, functioning, and health-related (HR) QOL for participants with non-cystic fibrosis bronchiectasis (NCFBE). The QOL-B contains 37 items in 8 domains (Respiratory Symptoms, Physical Functioning, Role Functioning, Emotional Functioning, Social Functioning, Vitality, Health Perceptions and Treatment Burden). Each of the 37 items is scored from 1 to 4, and each of the 8 domains scale scores is standardized on a 0-100 point scale, with higher scores representing fewer symptoms or better functioning and HR QoL. A positive change from Baseline indicates improvement in symptoms. For this outcome measure, change in the respiratory symptoms domain score from Baseline was reported. The analysis was based on mixed model for repeated measures (MMRM) approach.
| score on a scale | Brensocatib 10 mg | Brensocatib 25 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Quality of Life Questionnaire - Bronchiectasis (QOL-B) Respiratory Symptoms Domain Score Over 24 Week Treatment Period | 3.8 ± 0.78 | 5.9 ± 0.76 | 5.7 ± 0.77 |
FEV1 was used to assess lung function and is the maximum amount of air that can be forced out in one second after taking a deep breath. The percent predicted FEV1 was calculated by converting the spirometer reading to a percentage of what would be predicted as normal FEV1 based on a several personal factors (e.g. sex, age, etc.). Change from screening in percent predicted FEV1 to Week 24 was calculated as: percent predicted FEV1 value at Week 24 and percent predicted FEV1 value at screening. A positive percent change from screening indicates an improvement in lung function. The analysis was done using analysis of covariance (ANCOVA) with Pa colonization status and maintenance macrolide antibiotic use at Baseline as covariates.
| percent predicted FEV1 | Brensocatib 10 mg | Brensocatib 25 mg | Placebo |
|---|---|---|---|
| Change From Screening in Post-Bronchodilator Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) Over 24-Week Treatment Period | -0.3 ± 0.88 | -0.3 ± 0.85 | -1.8 ± 0.87 |
The concentration of active NE in sputum, was measured by the difference between the pre-treatment concentration and on-treatment concentration. In bronchiectasis, activation of neutrophils in the airway leads to release of NE which leads to damaged airway walls, mucus hypersecretion, exacerbated inflammation, which in turn affects neutrophil and macrophage functions, increasing the risk of infection. Negative change from Baseline indicates improvement.
| microgram/ milliliter (µg/mL) | Brensocatib 10 mg | Brensocatib 25 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Concentration of Active Neutrophil Elastase (NE) in Sputum | -2.928 ± 0.351 | -4.117 ± 0.322 | -1.409 ± 0.313 |
Pulmonary exacerbation was defined as having 3 or more of the following symptoms for at least 48 hours resulting in a physician's decision to prescribe antibiotics. 1. Increased cough 2. Increased sputum volume or change in sputum consistency 3. Increased sputum purulence 4. Increased breathlessness and/or decreased exercise tolerance 5. Fatigue and/or malaise 6. Hemoptysis A minimum of 4 weeks must have occurred between one exacerbation onset and the next. Any exacerbation that occurred less than 4 weeks from the prior exacerbation was not considered a new exacerbation.
| Participants | Brensocatib 10 mg | Brensocatib 25 mg | Placebo |
|---|---|---|---|
| Number of Participants Who Experienced a Pulmonary Exacerbation | 26 | 29 | 42 |
Collected over Baseline to Week 28 (End of study visit). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brensocatib 10 mg | 0/81 (0%) | 11/81 (13.6%) | 47/81 (58%) |
| Brensocatib 25 mg | 1/89 (1.1%) | 10/89 (11.2%) | 43/89 (48.3%) |
| Placebo | 0/85 (0%) | 19/85 (22.4%) | 33/85 (38.8%) |
| Event | Brensocatib 10 mg | Brensocatib 25 mg | Placebo |
|---|---|---|---|
| Infective exacerbation of bronchiectasisInfections and infestations | 5/81 | 4/89 | 9/85 |
| PneumoniaInfections and infestations | 0/81 | 4/89 | 3/85 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 0/81 | 0/89 | 2/85 |
| BronchitisInfections and infestations | 1/81 | 0/89 | 0/85 |
| AspergillomaInfections and infestations | 1/81 | 0/89 | 0/85 |
| Subcutaneous abscessInfections and infestations | 1/81 | 0/89 | 0/85 |
| Carotid artery occlusionNervous system disorders | 1/81 | 0/89 | 0/85 |
| Carotid artery stenosisNervous system disorders | 1/81 | 0/89 | 0/85 |
| Transient ischaemic attackNervous system disorders | 1/81 | 0/89 | 1/85 |
| LymphocytosisBlood and lymphatic system disorders | 1/81 | 0/89 | 0/85 |
| Event | Brensocatib 10 mg | Brensocatib 25 mg | Placebo |
|---|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 15/81 | 12/89 | 10/85 |
| HeadacheNervous system disorders | 8/81 | 12/89 | 3/85 |
| Sputum increasedRespiratory, thoracic and mediastinal disorders | 9/81 | 9/89 | 6/85 |
| DiarrhoeaGastrointestinal disorders | 5/81 | 3/89 | 9/85 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/81 | 8/89 | 2/85 |
| FatigueGeneral disorders | 3/81 | 7/89 | 6/85 |
| Upper respiratory tract infectionInfections and infestations | 6/81 | 4/89 | 4/85 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 6/81 | 1/89 | 1/85 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 6/81 | 2/89 | 1/85 |
| SinusitisInfections and infestations | 5/81 | 4/89 | 6/85 |
ITT population included all the participants who were randomized.
| Age, Continuous(years) | Brensocatib 10 mg | Brensocatib 25 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 64.6 ± 12.42 | 63.7 ± 12.67 | 64.0 ± 11.86 | 64.1 ± 12.27 |
| Sex: Female, Male(Participants) | Brensocatib 10 mg | Brensocatib 25 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 57 | 62 | 55 | 174 |
| Male | 25 | 25 | 32 | 82 |
| Ethnicity (NIH/OMB)(Participants) | Brensocatib 10 mg | Brensocatib 25 mg | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 2 | 4 | 0 | 6 |
| Not Hispanic or Latino | 80 | 83 | 87 | 250 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Brensocatib 10 mg | Brensocatib 25 mg | Placebo | Total |
|---|---|---|---|---|
| Race — Caucasian (White) | 76 | 78 | 71 | 225 |
| Race — African American/Black of African origin | 0 | 2 | 2 | 4 |
| Race — Asian | 5 | 5 | 13 | 23 |
| Race — American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Race — Native Hawaiian or Other Pacific Islander | 1 | 1 | 1 | 3 |
| Race — Other | 0 | 1 | 0 | 1 |
Showing the first 100 of 108 sites across 14 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2017 to primary completion in Dec 2019, 25 months.
Results were first posted in Feb 2023, 3 years 1 month after primary completion. A results delay was requested in Dec 2020.
Of 24 phase 2 interventional studies under Bronchiectasis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 32. This study's 25 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brensocatib